P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000846712.74284.0f |
| _version_ | 1797287214775795712 |
|---|---|
| author | Y. Lin T. Martin J. G. Berdeja A. Jakubowiak M. Agha A. D. Cohen A. Deol M. Htut A. Lesokhin N. C. Munshi E. O’Donnell C. C. Jackson T.-M. Yeh A. Banerjee E. Zudaire D. Madduri C. Zhou L. Pacaud S. Z. Usmani S. Jagannath |
| author_facet | Y. Lin T. Martin J. G. Berdeja A. Jakubowiak M. Agha A. D. Cohen A. Deol M. Htut A. Lesokhin N. C. Munshi E. O’Donnell C. C. Jackson T.-M. Yeh A. Banerjee E. Zudaire D. Madduri C. Zhou L. Pacaud S. Z. Usmani S. Jagannath |
| author_sort | Y. Lin |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:29:43Z |
| format | Article |
| id | doaj.art-2d4dfbb6f6e441b09f6af18692e9f274 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:29:43Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-2d4dfbb6f6e441b09f6af18692e9f2742024-03-02T06:40:50ZengWileyHemaSphere2572-92412022-06-01685185210.1097/01.HS9.0000846712.74284.0f202206003-00851P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDYY. Lin0T. Martin1J. G. Berdeja2A. Jakubowiak3M. Agha4A. D. Cohen5A. Deol6M. Htut7A. Lesokhin8N. C. Munshi9E. O’Donnell10C. C. Jackson11T.-M. Yeh12A. Banerjee13E. Zudaire14D. Madduri15C. Zhou16L. Pacaud17S. Z. Usmani18S. Jagannath191 Mayo Clinic, Rochester, MN2 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA3 Sarah Cannon Research Institute, Nashville, TN4 University of Chicago, Chicago, IL5 UPMC Hillman Cancer Center, Pittsburgh, PA6 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA7 Karmanos Cancer Institute, Wayne State University, Detroit, MI8 City of Hope Comprehensive Cancer Center, Duarte, CA9 Memorial Sloan Kettering Cancer Center, New York, NY10 Dana-Farber Cancer Institute, Harvard Medical School11 Massachusetts General Hospital, Harvard Medical School, Boston, MA12 Janssen R&D, Raritan, NJ12 Janssen R&D, Raritan, NJ13 Janssen R&D, Spring House, PA13 Janssen R&D, Spring House, PA12 Janssen R&D, Raritan, NJ14 Legend Biotech USA, Piscataway, NJ14 Legend Biotech USA, Piscataway, NJ9 Memorial Sloan Kettering Cancer Center, New York, NY15 Mount Sinai Medical Center, New York, NY, United States of Americahttp://journals.lww.com/10.1097/01.HS9.0000846712.74284.0f |
| spellingShingle | Y. Lin T. Martin J. G. Berdeja A. Jakubowiak M. Agha A. D. Cohen A. Deol M. Htut A. Lesokhin N. C. Munshi E. O’Donnell C. C. Jackson T.-M. Yeh A. Banerjee E. Zudaire D. Madduri C. Zhou L. Pacaud S. Z. Usmani S. Jagannath P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY HemaSphere |
| title | P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY |
| title_full | P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY |
| title_fullStr | P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY |
| title_full_unstemmed | P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY |
| title_short | P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY |
| title_sort | p961 ciltacabtagene autoleucel a bcma directed car t cell therapy in patients with relapsed refractory multiple myeloma 2 year post lpi results from the phase 1b 2 cartitude 1 study |
| url | http://journals.lww.com/10.1097/01.HS9.0000846712.74284.0f |
| work_keys_str_mv | AT ylin p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT tmartin p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT jgberdeja p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT ajakubowiak p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT magha p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT adcohen p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT adeol p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT mhtut p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT alesokhin p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT ncmunshi p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT eodonnell p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT ccjackson p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT tmyeh p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT abanerjee p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT ezudaire p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT dmadduri p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT czhou p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT lpacaud p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT szusmani p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study AT sjagannath p961ciltacabtageneautoleucelabcmadirectedcartcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma2yearpostlpiresultsfromthephase1b2cartitude1study |